# US 6,730,694 B1 · sPLA2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,694 B1
- Document ID: US6730694B1
- Status: Granted
- Kind: B1
- Application number: 10/332,480
- Filed: 2003-01-07
- Granted: 2004-05-04
- Earliest claimed: 2003-01-07
- Assignees: Eli Lilly and Company
- Inventors: Douglas Wade Beight; John Michael Morin, Jr.; Jason Scott Sawyer; Edward C R Smith
- Web page: https://patentgrep.com/patent/US6730694B1

## CPC

- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

## Claims

### Claim 1

A substituted pyrrolo compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;
wherein;
A is S, SO, SO2, O, or NR, and R is a non-interfering substituent;
R1 is selected from groups (a), (b), and (c) wherein;
(a) is C7-C20 alkyl, C7-C20 haloalkyl, C7-C20 alkenyl, C7-C20 alkynyl, carbocyclic radical, or heterocyclic radical, or
(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or
(c) is the group —(L1)—R11; where, —(L1)— is a divalent linking group of 1 to 8 atoms and where R11 is a group selected from (a) or (b);
R2 is hydrogen, or a group containing 1 to 4 non-hydrogen atom plus any required hydrogen atoms;
R3 is —(L3)— Z, where —(L3)— is a divalent linker group selected from a bond or a divatent group selected from;
and Z is selected from a group represented by the formulae,
wherein, X is oxygen or sulfur; and Ra is selected from hydrogen, C1-C8 alkyl, aryl, C1-C8 alkaryl, C1-C8 alkoxy, aralkyl and —CN;
R4 is the group hydrogen; or the group WR4e wherein W is oxygen, Sulfur or NH, and R4e is an alkyl, aryl or an alkylaryl group; or the group —(La)—(acidic group); wherein —(La)—, is an acid linker having an acid linker length of 1 to 8; or the group —(Lh)—(N-hydroxyfunctional amide group); wherein —(Lh)—, is an N-hydroxyfunctional amide linker having an N-hydroxyfunctional amide linker length of 1 to 8;
or the group —(Lc)—(acylamino acid group); wherein —(Lc)—, is an acylamino acid linker having an acylamino acid linker length of 1 to 8;
R5 is selected from hydrogen, a non-interfering substituent, or the group, —(La)—(acidic group); wherein —(La)—, is an acid linker having an acid linker length of 1 to 8.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R2 is hydrogen, C2-C4 alkyl, C2-C4 alkenyl, —O—(C1-C3 alkyl), —S—(C1-C3 alkyl), C3-C4 cycloalkyl, —CF3, halo, —NO2, —CN, or —SO3.

### Claim 3 (depends on 1)

The compound of claim 1 wherein the acid linker group, —(La)—, for R4 is a divalent group selected from,
where R40, R41, R42, and R43 are each independently selected from hydrogen, C1-C8 alkyl.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R4 is hydrogen.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R4 is WR4e, and wherein W is oxygen, and R4e is a group selected from hydrogen, (C1-C4)alkyl, and aryl.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R4 is the group —(Lc)—(acylamino acid group).

### Claim 7 (depends on 1)

The compound of claim 1 wherein R5 is hydrogen.

### Claim 8 (depends on 1)

The compound of claim 1 wherein A is sulfur.

### Claim 9 (depends on 1)

The compound of claim 1 wherein for R3, Z is the group represented by the formula;
and the linking group —(L3)— is a bond; and Ra is hydrogen, methyl, ethyl, propyl, isopropyl, phenyl or benzyl.

### Claim 10 (depends on 1)

The compound of claim 1 wherein for R3, Z is the group represented by the formula;
and the linking group —(L3)— is a bond; and Ra is hydrogen.

### Claim 11 (depends on 1)

The compound of claim 1 wherein for R3, Z is the group represented by the formula;
and the linking group —(L3)— is a bond.

### Claim 12 (depends on 1)

The compound of claim 1 wherein for R3, Z is the group represented by the formula;
and the linking group —(L3)— is a bond.

### Claim 13 (depends on 1)

The compound of claim 1 wherein for R1 the divalent linking group —(L1)— is selected from a group represented by the formulae (Ia), (Ib), (Ic), (Id), (Ie), and (If):
where Q1 is a bond or any of the divalent groups Ia, Ib, Ic, Id, and Ie and R10 is independently —H, C1-8 alkyl, C1-8 haloalkyl or C1-8 alkoxy.

### Claim 14 (depends on 1)

The compound of claim 1 wherein the linking group —(L1)— of R1 is —(CH2)— or —(CH2—CH2)—.

### Claim 15 (depends on 1)

The compound of claim 1 wherein the linking group —(L11)— of R11 is a bond and R11 is —(CH2)m—R12 wherein m is an integer from 1 to 6, and R12 is a group represented by the formula:
wherein a, c, e, n, q and t are independently an integer from 0 to 2, R13 and R14 are independently selected from a halogen, C1 to C8 alkyl, C1 to C8 alkyloxy, C3 to C8 alkylthio, aryl, heteroaryl, and C1 to C8 haloalkyl, α is an oxygen atom or a sulfur atom, L5 is a bond, —(CH2)v—, —C═C—, —CC—, —O—, or —S—, v is an integer from 0 to 2, β is —CH2— or —(CH2)2—, γ is an oxygen atom or a sulfur atom, b is an integer from 0 to 3, d is an integer from 0 to 4, f, p, and w are independently an integer from 0 to 5, r is an integer from 0 to 7, and u is an integer from 0 to 4, or is (e) a member of (d) substituted with at least one substituent selected from the group consisting of C1 to C6 alkyl, C1 to C8 alkyloxy, C1 to C8 haloalkyloxy, C1 to C8 haloalkyl, aryl, and a halogen.

### Claim 16 (depends on 1)

The compound of claim 1 wherein for R1 the group R11 is a substituted or unsubstituted carbocyclic radical selected from the group consisting of cycloalkyl, cycloalkenyl, phenyl, spiro[5.5]undecanyl, naphthyl, norbornanyl, bicycloheptadienyl, toluyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzylyl and related bibenzylyl homologues represented by the formula (a):
where n is a number from 1 to 8.

### Claim 17

A substituted pyrrole compound represented by the formula (II), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;
wherein;
R22 is selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, —F, —CF3, —Cl, —Br, or —O—C3;
R13 is C2-C8 alkyl; and t is an integer from 0 to 5″.

### Claim 18

A substituted pyrrole compound represented by the formulae (C1), (C2), (C3), (C4), (C5), (C6), (C7), (C8), (C9), (C10), (C11), (C12), and (C13):
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 19 (depends on 1)

A pharmaceutically formulation comprising a substituted pyrrole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

### Claim 20 (depends on 1)

A method of inhibiting sPLA2 mediated release of fatty acid which comprises contacting sPLA2 with a therapeutically effective amount of a substituted pyrrole compound according to claim 1; and t is an integer from 0 to 5″.

### Claim 21 (depends on 1)

A method of treating a mammal to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises administering to said mammal a pharmaceutically effective amount of a compound according to claim 1.

### Claim 22 (depends on 1)

A pharmaceutical formulation comprising an effective amount of the compound according to claim 1 for the treatment of Inflammatory Diseases.

### Claim 23 (depends on 1)

A pharmaceutical formulation comprising an effective amount of the compound according to claim 1 useful as an inhibitor of sPLA2 mediated release of fatty acid.
or a pharmaceutically acceptable salt or prodrug thereof.
